Read More Pharma Industry News X4 Pharmaceuticals (NASDAQ: XFOR) gets FDA fast track for mavorixafor in chronic neutropenia X4 Pharmaceuticals (XFOR) secures FDA Fast Track for mavorixafor in chronic neutropenia, targeting trial completion in 2025 and results in 2026. byPallavi MadhirajuJune 10, 2025